MRNA vs RGEN · rev $145.0M vs P/E 143, rev $204.1M
Moderna Inc (MRNA) versus Repligen Corporation (RGEN) — a side-by-side from cached financials, not a winner call.
Moderna Inc (MRNA) is a biotechnology company listed on NASDAQ. It is led by Stéphane Bancel M.B.A..
Repligen Corporation (RGEN) is a medical instruments & supplies company listed on NASDAQ.
Latest reported MRNA revenue for 2026-06-30 was $145.0M. Net income was -$782.0M. Revenue was down 62.7% from 2026-03-31 to 2026-06-30. MRNA currently screens at market cap $24.52B.
Latest reported RGEN revenue for 2026-06-30 was $204.1M. Net income was $5.0M. Revenue was up 5.1% from 2026-03-31 to 2026-06-30. RGEN currently screens at market cap $7.43B and trailing P/E 143.1.
MRNA currently screens at market cap $24.52B. RGEN currently screens at market cap $7.43B and trailing P/E 143.1.
Not investment advice. Open the MRNA and RGEN stock pages for the full models.
Not investment advice.